Cerefolin Brain Wellness™ Product Info for HCPs

Same Efficacy, No Major Allergens*or Dyes

There’s hope for patients with Mild Cognitive Impairment (MCI). Targeted nutrition provided by our clinically tested* formula has been shown to protect and preserve aspects of brain health.

Download Product Information

Ingredients

Dietary ingredients

Other ingredients

Microcrystalline Cellulose and Silicon Dioxide, Hypromellose, Magnesium Stearate (NF, Vegetable Source).

Metafolin® is a registered trademark of Merck KGaA, Darmstadt, Germany.

Manufactured in the USA with high-quality ingredients sourced both from the US and globally.

Recommended Use

The usual adult dose is one caplet once daily (1 caplet QD) or as directed under medical supervision.

Contraindications

Cerefolin Brain Wellness™ is contraindicated in patients with known hypersensitivity to any of the components contained in this product.

Dual Action Formula

Targeted nutrition for Mild Cognitive Impairment (MCI).

Improves

Brain Health
- Supports acetylcholine and glutathione production ^6,11,12
- Enhances vascular blood flow and cellular regeneration^10,13-15
- Lowers elevated homocysteine levels^1,7
Memory & Focus
- Supports memory retention and executive function^2*
- Helps patients maintain focus and perform memory-related tasks.^2-4*
Concentration
- Individuals taking Cerefolin Brain Wellness™ reported improved performance on tasks involving sequencing and response inhibition, supporting better daily concentration. ^4*

Slows

Cognitive Decline
- Slows the progression of cognitive decline, helping patients maintain essential cognitive function longer. ^3*
Brain Atrophy
- In a clinical study, Cerefolin Brain Wellness™ was shown to slow brain atrophy in hyperhomocysteinemia patients by up to 11.2 times compared to patients without hyperhomocysteinemia & not taking Cerefolin Brain Wellness™, helping preserve brain health and structure in those at risk of cognitive decline.^1*

Cerefolin Brain Wellness™ Is:

Icon featuring wheat, milk, fish, and nut with diagonal line through them to depict free from allergens

Major Allergen Free

Milk, eggs, fish or shellfish, tree nuts, peanuts, wheat, sesame and soy

Icon featuring ink bottle with diagonal line through it to depict free from dyes

Dye FREE

Sugar FREE

Icon featuring scientific symbol for titanium with diagonal line through it to depict free from titanium

Titanium Dioxide FREE

Icon featuring glass beaker with diagonal line through it depicting no preservatives

Preservative FREE

Icon featuring salt shaker with diagonal line through it to depict free from sodium

Sodium FREE

Non-GMO

Vegan

Icon featuring coffee bean with diagonal line through it to show free from caffeine

Caffeine FREE

Icon featuring wheat stalk with diagonal line through it to depict free from gluten

Gluten FREE

Results after >1 year with Cerefolin Brain Wellness™*

In a retrospective trial (n=109), longer use of Cerefolin Brain Wellness™* (median=17.3 months) resulted in a significant slowing of decline in Memory Performance Index compared with no use of Cerefolin Brain Wellness™* (p<0.046, Chi-squared).¹
Further effects observed included a reduced rate of decline in other cognitive measures, such as memory and constructional praxis.²
An analytical model showed that duration of use must exceed a minimum period of at least 1 year to slow the rate of cognitive decline.³

See More Clinical Data

Setting Expectations for Your Patients

Extended use of Cerefolin Brain Wellness™* (#90 1qd refill x3) can lead to sustained cognitive health and provide continued support to slow the progression of cognitive and memory decline.¹

High Satisfaction & Intent to Continue Among Patients

We surveyed people at day 45 and day 90 of taking Cerefolin Brain Wellness™*. At the second follow-up, 94% of patients said they intend to continue taking this product.⁴

Disclaimers

Cerefolin Brain Wellness™ is a targeted nutrition product for the clinical dietary management of mild cognitive impairment with hyperhomocysteinemia and is specially formulated to meet the distinctive nutritional requirements for this condition. Use under medical supervision.

§ Images don’t portray actual consumers and are for illustration purposes only.

|| Testimonials based on experience with CerefolinNAC®*.

* Cerefolin Brain Wellness™, formerly known and studied as CerefolinNAC®, is the same trusted and effective product that is now free from major allergens (milk, eggs, fish, shellfish, tree nuts, peanuts, wheat, sesame and soy), dyes, and colorants.

† By submitting this information, I hereby give Alfasigma USA, Inc. authorization to release, reproduce, use or distribute information about me, in original or modified form, for promotional and educational purposes in all forms of media, including print, broadcast or Internet. This information may include my medical information if I choose to submit any. I understand my information may be shared with a third party working on Alfasigma USA, Inc.’s behalf for promotional or educational purposes. I also understand that I may be contacted by this third party or Alfasigma USA, Inc. for more information.

^†† This product should be taken under medical supervision, and you should consult your healthcare provider before taking this for mild cognitive impairment.

References

Shankle WR, et al. J Alzheimer’s Dis. 2016 Oct 4;54(3):1073-1084
Shankle WR, et al. J Aging Res Clin Prac. 2013
Hara J, et al. Nutr Health Aging. 2015
Alfasigma USA. Data on File. PLUS Program: Patient Survey Results 2012. USA
Data on file. Support data 2019-2024. Alfasigma USA.
Chan A, et al. J Nutr Health Aging 2008;12(4):252-61.
de Jager CA. et al. Int J Geriatr Psychiatry. 2012 Jun:27(6):592-600.
Merrill E, et al. Am. J. Epidemiol. 2005 Oct;162(7):644-53.
Altern Med Rev 2000 Oct;5(5):467-71.
de Jager CA. Neurobiol Aging 2014;35(suppl 2):535-9.
Atkuri KR, et al. Curr Opin Pharmacol. 2007. 2007
N-acetylcysteine. Monograph. Alt Med Rev. 2000
Antoniades C, et al. Circulation. 2006.
Calderón-Ospina CA, et al. CNS Neurosci Ther. 2020.
Kimura, A.M et al. Alzheimer’s Dement. 2021.
Rogers JD, et al. Arch Neurol. 2003 Jan;60(1):59-64.
Smith AD, et al. J Alzheimer’s Dis.
Seshadri S, et al. N Engl J Med. 2002.
Yao Y, et al. J Geriatr Cardiol. 2017.
Diaz-Arrastia R, et al. Arch Neurol. 2000.
Keller, A.C., et al. J. Appl. Physiol. 2019.
Zhu Z, et al. Climacteric. 2020.
Estrada, D.A. et al. Am. J. Hematol. 2001.
Luzzi S, et al. Biomedicines. 2022.
Diekman, M. J. M., et al. Clin. Endocrinol. (Oxf) 2001.
Paknahad Z, et al. Int J Prev Med. 2012.
Desouza, C, et al. Drugs. 2002.
P. S. Myles et al. Br. J. Anaesth. 2008.
Fallah S, et al. J Clin Lab Anal. 2012.
Lerman, et al. AJMS., 2022.
Troen AM, et al. Proc Natl Acad Sci U S A. 2003.
Haj Mouhamed D, et al. Clin Chem Lab Med. 2011.

ALUSA-01273

Same Efficacy, No Major Allergens*or Dyes